Two Seattle-area health and longevity startups are merging their bets on the future of "biological age": Viome Life Sciences has acquired Circulate Health, a pioneer of therapeutic plasma exchange (TPE) — the blood-cleaning procedure embraced by biohackers and longevity clinics. The parties did not disclose specifics but said the deal was valued between $15 million and $50 million.
Viome sells at-home test kits for saliva, blood and stool, analyzes RNA biomarkers, and offers personalized supplements; its diagnostics include a test for early detection of oral and throat cancer that has received FDA breakthrough device designation. Circulate operates TPE machines staffed by its own trained nurses, aiming to remove inflammatory factors, microplastics and compounds associated with aging from the blood. It launched in January 2024 after two years in stealth, had raised $14 million, and ran clinics at 40 health and longevity sites, mostly in the U.S.
Combined with Viome's clinic partnerships, the merged company could reach up to 400 sites. It has 115 full-time employees; Circulate co-founder Brad Younggren becomes president of the new clinical group, Viome Pro, which includes diagnostics, cancer detection and plasma exchange. Viome was founded a decade ago and has raised about $250 million.
Both fields face skepticism: researchers have questioned the scientific rigor of microbiome test kits, and medical experts called a 2025 Circulate study in Aging Cell — which reported lower biological age in 42 adults after repeated treatments — of uncertain long-term significance. Circulate published a separate 2026 study in the Journal of Clinical Apheresis suggesting its protocols reduced microplastics in blood. "We'll continue to do research," Younggren said. "We're going to be doing a trial combining plasma exchange with all the technologies that already exist under the hood at Viome."
